About US
Contact us
-
India axes exports of Gilead Sciences' remdesivir, plots boost to local production as COVID cases mount: reportsIndia is one of the world's biggest manufacturers of drugs and vaccines, but that hasn't made it immune to COVID-19 supply instability. Now, the government is locking up at least one treatmentfor its2021/4/13
-
FDA joins Europe in probing rare blood clots after Johnson & Johnson's COVID-19 vaccineDrug regulators in Europe last week flagged rare but “serious” cases of blood clotsin people who had receivedJohnson & Johnson’s COVID-19 vaccine.But it’s not just European regulatorstaking a clo2021/4/13
-
FibroGen admits to messing with roxadustat safety data, upending hopes for the AZ-partnered anemia drugIn a stunning revelation, FibroGen admitted to presenting roxadustat data manipulated to make the anemia drug look safer than it is. The late-Tuesday announcement sent FibroGen shares tumbling and pr2021/4/9
-
J&J scores backing from Chamber of Commerce, PhRMA and more in Supreme Court appeal of $2.1B talc verdictJohnson & Johnson has ginned upmajor support in its quest to challenge a $2.1 billionverdict over claims that its talc-based powders cause cancer. The U.S. Chamber of Commerce and other business2021/4/9
-
AstraZeneca COVID-19 shot tagged with new warning in EU, highlighting rare blood clot riskEurope’s drug regulator has been probingcasesof rare blood clots in AstraZeneca COVID-19 vaccine recipients since mid-March—and now it has confirmed a possible link. The agency stressed that the bene2021/4/7
-
BeiGene's massive biologics plant in China wins first commercial manufacturing nodBeiGene is taking over manufacturingforits China-approved PD-1 checkpoint inhibitorthanks to a new approval for a massive biologics factory. The China National Medical Products Administration (NMPA)2021/4/6
-
Nitto Denko lays out $226M to boost oligonucleotide production in a bustling RNA marketWith oligonucleotides on the rise totreat rare diseases and cancers, Japanese manufacturerNitto Denko is laying big plans. Nitto will plug a whopping25 billion yen ($225.93 million) into its Massachu2021/4/2
-
AstraZeneca's COVID vaccine faces new round of restrictions—even after the EMA's renewed backingSeveral countries stopped using AstraZeneca's COVID-19 shot earlier this month after reports of rare blood clots following vaccination.The European Medicines Agency sought to add clarity to the issue2021/4/2
-
Up to 15M Johnson & Johnson coronavirus vaccine doses ruined due to human error: NYTJohnson & Johnson's COVID-19 vaccine rollout has beenslower than expected in the U.S., with just 6.8 million dosesdeliveredto states in the first month.Now, The New York Times has revealed behind2021/3/30
-
Apotex yanks ADHD med after traces of schizophrenia drug turn up in a single lotWhen traces of the wrong drug appearin a tablet, it's best to err on the side of caution. Apotex did just that Wednesday, when it said it would pullseveralbatches of an attention deficit hyperactivit2021/3/30